Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study

Trial Profile

Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2019

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2019 Primary endpoint (Outcome of the neutralization test (number of subjects with neutralization titres against TBE virus 10)) has been met as per results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
    • 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
    • 13 Dec 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top